November 12, 2019 04:32 PM ET (BZ Newswire) -- Biotech
New analysis from Phase 4 study in RA showed that statistically significant improvement from baseline in patient-reported outcomes for pain, fatigue, physical functioning and work-related impairment was associated with Acthar Gel treatment - -- Results from an exploratory analysis showed bone and cartilage biomarker levels in patients treated with Acthar Gel were largely stable and markers of bone degeneration remained stable.
STAINES-UPON-THAMES, United Kingdom, Nov. 12, 2019 /PRNewswire/
Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced data on patient-reported outcomes (PROs) showing Acthar® Gel (repository corticotropin injection) improved disease measures that impact rheumatoid arthritis (RA) patients with persistently active disease, as well as new data from an exploratory analysis. The data originate from new analyses from Mallinckrodt's Phase 4 study of Acthar Gel in RA patients with persistently active disease and was recently presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, held Nov. 8-13 in Atlanta.
